4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
产品详情
CL2A-SN-38 是 drug-linker conjugate,由 linker CL2A 和 毒性分子 SN-38 连接而成的,可用来制备抗体偶联药物 (ADC)。CL2A-SN-38 针对人类实体瘤表现出特异性的抗肿瘤作用。SN-38 是一种 DNA Topoisomerase I 抑制剂。CL2A-SN-38 采用可水解linker,可在肿瘤细胞内和肿瘤微环境中递送活性药物,产生旁观者效应。
生物活性
CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active drugs within tumor cells and in the tumor microenvironment, resulting in bystander effects.
性状
Solid
IC50 & Target[1][2]
Camptothecins
体内研究(In Vivo)
CL2A-SN-38 coupled to the anti-Trop-2 humanized antibody hRS7 (intraperitoneal injection, 0.2 or 0.4 mg/kg, twice weekly, 4 weeks) can both significantly inhibit tumor growth in mice with human colon (COLO 205) or pancreatic (Capan-1) tumour xenografts. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
参考文献
[1]. Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69.[2]. Thomas M Cardillo, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69.
溶解度数据
In Vitro: DMSO : 100 mg/mL (67.54 mM; Need ultrasonic)配制储备液